檢索結果 - Brenda J. Weigel

Refine Results
  1. 1
    Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

    Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group 由 AeRang Kim, Brigitte C. Widemann, Mark Krailo, Nalini Jayaprakash, Elizabeth Fox, Brenda J. Weigel, Susan M. Blaney

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

    Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group earl... 由 Wendy B. London, Rochelle Bagatell, Brenda J. Weigel, Elizabeth Fox, Dongjing Guo, Collin Van Ryn, Arlene Naranjo, Julie R. Park

    出版 2017
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

    Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies... 由 Brenda J. Weigel, Sarah Cooley, Todd E. DeFor, Daniel J. Weisdorf, Angela Panoskaltsis‐Mortari, Wei Chen, Bruce R. Blazar, Jeffrey S. Miller

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)

    Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD) 由 Patricia A. Taylor, Michael Ehrhardt, Christopher J. Lees, Jakub Tolar, Brenda J. Weigel, Angela Panoskaltsis‐Mortari, Jonathan S. Serody, Volker Brinkmann, Bruce R. Blazar

    出版 2007
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology gr... 由 Lars M. Wagner, Maryam Fouladi, Atif Ahmed, Mark Krailo, Brenda J. Weigel, Steven G. DuBois, L. Austin Doyle, Helen Chen, Susan M. Blaney

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia

    A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia 由 Michael J. Burke, Jatinder K. Lamba, Stanley Pounds, Xueyuan Cao, Yogita Ghodke‐Puranik, Bruce R. Lindgren, Brenda J. Weigel, Michael R. Verneris, Jeffrey S. Miller

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

    Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With Hig... 由 Brenda J. Weigel, Elizabeth Lyden, James R. Anderson, William H. Meyer, David M. Parham, David A. Rodeberg, Jeff M. Michalski, Douglas S. Hawkins, Carola A.S. Arndt

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Phase I trial of Seneca Valley Virus (NTX‐010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group

    Phase I trial of Seneca Valley Virus (NTX‐010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group 由 Michael J. Burke, Charlotte H. Ahern, Brenda J. Weigel, John T. Poirier, Charles M. Rudin, Ying‐Bei Chen, Timothy P. Cripe, M. Brooke Bernhardt, Susan M. Blaney

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

    Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group 由 Brenda J. Weigel, Suman Malempati, Joel M. Reid, Stephan D. Voss, Steven Y. Cho, Helen X. Chen, Mark Krailo, Doojduen Villaluna, Peter C. Adamson, Susan M. Blaney

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study

    Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncol... 由 Rochelle Bagatell, Robin E. Norris, Ashish M. Ingle, Charlotte H. Ahern, Stephan D. Voss, Elizabeth Fox, Anthony Little, Brenda J. Weigel, Peter C. Adamson, Susan M. Blaney

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

    Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Con... 由 Yaël P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda J. Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, Susan M. Blaney

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)

    A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot... 由 James I. Geller, Elizabeth Fox, Brian Turpin, Stuart L. Goldstein, Xiaowei Liu, Charles G. Minard, Rachel A. Kudgus, Joel M. Reid, Stacey L. Berg, Brenda J. Weigel

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

    A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 由 Kara L. Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard, Stephan D. Voss, Stacey L. Berg, Brenda J. Weigel, Crystal L. Mackall

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

    A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consorti... 由 Mignon L. Loh, Sarah K. Tasian, Karen R. Rabin, Patrick A. Brown, Daniel Magoon, Joel M. Reid, Xuejun Chen, Charlotte H. Ahern, Brenda J. Weigel, Susan M. Blaney

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

    Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers 由 Melissa A. Geller, Sarah Cooley, Peter A. Argenta, Levi S. Downs, Linda F. Carson, Patricia L. Judson, Rahel Ghebre, Brenda J. Weigel, Angela Panoskaltsis‐Mortari, Julie Curtsinger, Jeffrey S. Miller

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report

    Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report 由 Jack Su, Lindsay Kilburn, David B. Mansur, Mark Krailo, Allen Buxton, Adesina Adekunle, Amar Gajjar, Peter C. Adamson, Brenda J. Weigel, Elizabeth Fox, Susan M. Blaney, Maryam Fouladi

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112)

    A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112) 由 Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Tong Lin, Brenda J. Weigel, Susan M. Blaney

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study 由 Yaël P. Mossé, Stephan D. Voss, Megan S. Lim, Delphine C.M. Rolland, Charles G. Minard, Elizabeth Fox, Peter C. Adamson, Keith D. Wilner, Susan M. Blaney, Brenda J. Weigel

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma

    Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma 由 Kristina A. Cole, Heba Ijaz, Lea F. Surrey, Mariarita Santi, Xiaowei Liu, Charles G. Minard, John M. Maris, Stephan D. Voss, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

    Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia 由 Qing Zhou, Meghan E. Munger, Rachelle G. Veenstra, Brenda J. Weigel, Mitsuomi Hirashima, David H. Munn, William J. Murphy, Miyuki Azuma, Ana C. Anderson, Vijay K. Kuchroo, Bruce R. Blazar

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: